As of May 22
| +0.10 / +0.80%|
The 6 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 15.50, with a high estimate of 16.00 and a low estimate of 13.00. The median estimate represents a +23.41% increase from the last price of 12.56.
The current consensus among 7 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.